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Abstract
Background: Type 1 Diabetes Mellitus (Type 1 DM) affects the psychological and emotional well-being of patients
and their families. This study aims to evaluate the health- related quality of life (HRQoL) of people with Type 1 DM
in Brazil, a country of continental proportions, using the EuroQol questionnaires.
Methods: This was a retrospective, cross-sectional, multicenter study performed by the Brazilian Type 1 Diabetes
Study Group, by analyzing EuroQol scores from 3,005 participants with Type 1 DM, in 28 public clinics in Brazil. Data
on demography, economical status, chronic complications, glycemic control and lipid profile were also collected.
Results: The assessment of HRQoL by the EuroQol showed that the average score assigned to general health in
Brazil is markedly lower than those found in two other Type 1 DM population-based studies conducted in Europe
(EQ–VAS from the Netherlands, the United Kingdom and Brazil were 80.8 ± 15.2, 75.1 ± 18.4 and 72.5 ± 22, respectively).
Additionally, our data suggest that a better glycemic control could positively impact the HRQoL of people with Type 1
DM, implying that each 1 % reduction in glycated haemoglobin might lead to an increase of 1.5 points in general
health status assessed by the EuroQol.
Conclusions: This is a population-based study evaluating the HRQoL of people with Type 1 DM in Brazil. Our data
indicate a worse quality of health of people with Type 1 DM in Brazil in comparison to Europe, and suggest that a
better glycemic control could positively impact the HRQoL of these individuals. However, this study points to the
existence of additional factors not yet evaluated that could be determinant in the HRQoL of these people.
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Background
Type 1 Diabetes Mellitus (Type 1 DM) affects the
psychological and emotional well-being of patients and
their families [1]. It has been shown that individuals with
diabetes have reduced health-related quality of life
(HRQoL) compared with the general population [2], and
that poor HRQoL in patients with diabetes is associated
with adverse outcomes, including increased mortality
[3]. However, most of the studies on diabetes and
HRQoL have been conducted in type 2 diabetic patients,
and data in developing countries are still limited [4–6].
A large number of factors might be responsible for the
negative impact of diabetes on quality of life (QoL), such
as fear of hypoglycemia or of secondary complications,
future worries on stigmatization, loss of flexibility, poor
self-image, overprotection, age, economic class, education,
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ethnicity, knowledge regarding the disease and the daily
demands of diabetes therapy (i. e. insulin therapy, blood
glucose monitoring) [7–9]. The impact of glycemic con-
trol on the QoL of people with diabetes remains contro-
versial. Some studies have shown no effect of an intensive
glycemic control on QoL [10, 11]. In opposition, the Hvi-
doere Study Group has suggested that the outcomes of
diabetes care, assessed by glycated haemoglobin (HbA1c),
are better in individuals with a better QoL [12].
When addressing this topic, in order to avoid using
confusing terminology, which could lead to misleading
conclusions, it is important to clarify that health status,
quality of health, HRQoL, and QoL cannot be assumed
as interchangeable terms [13]. QoL is a multifaceted and
dynamic concept, considering its highly subjective and
individual nature [14, 15]. It has been defined as “how
good or bad a person feels their life to be” [15]. Health
status, quality of health and HRQoL, on the other hand,
refer to how people feel about their health (physical and
mental) [4]. Therefore, quality of health and QoL are
not the same thing [15]. Impaired health or well-being
may lead to, or be experienced at the same time as im-
paired quality of life—but not necessarily. Furthermore,
excellent health does not infer excellent quality of life [16].
Once established the conceptual difference between
these terms, it is also essential to determine the instruments
suitable to assess each of them in diabetes research. A sys-
tematic literature search, including over 6,000 abstracts,
found that some instruments are better to assess QoL
[World Health Organization Quality of Life (WHOQOL),
Diabetes Quality of Life (DQOL) and Audit of Diabetes-
Dependent Quality of Life (ADDQoL)], and others more
accurately measure health status [Short-Form 36 (SF-36),
EuroQoL 5-Dimension (EQ-5D)] [14].
The Brazilian Type 1 Diabetes Study Group performed
a survey that analyzed the demographic, clinical, labora-
torial and economic data of 3,591 patients with Type 1
DM who received medical care at public clinics in Brazil.
The purpose of the present study was to analyze the asso-
ciation between a better glycemic control and HRQoL, by
using the EuroQol questionnaires, as well as investigate
additional variables that could influence the HRQoL of
these individuals. In parallel, we aimed to evaluate the
HRQoL of people with Type 1 DM in the Southern hemi-
sphere, in a country of continental proportions such as
Brazil, and establish a comparison with worldwide data.
Methods
Study design
The Brazilian Type 1 Diabetes Study Group performed a
retrospective, cross-sectional and multicenter study on
people with Type 1 DM between December 2008 and
December 2010, in 28 public clinics of the secondary
and tertiary care level, located in 20 cities (population
greater than 100,000), in the five Brazilian geographical
regions (North, Northeast, Southeast, South and Midwest).
For statistical purposes, North and Northeast were
grouped.
Patients
All patients received health care from the National Brazilian
Health Care System (NBHCS), and were treated by an
endocrinologist in secondary or tertiary care settings. Al-
though the study did not include people treated at primary
level, these individuals represent a minority of people with
Type 1 DM in Brazil. We included on this study patients
diagnosed with Type 1 DM by a physician (based on a typ-
ical clinical presentation as well as the need of using insulin
continuously since the diagnosis), with follow-up time in
each center greater than or equal to 6 months, and older
than 10 years old. Exclusion criteria were pregnancy,
lactation, history of acute infectious processes or diabetic
ketoacidosis in the 3 months prior to assessment.
Clinical and laboratorial data
Data of interest for the analysis of HRQoL were obtained
from questionnaires self-completed by the patients, in
addition to records obtained from medical charts.
Trained physicians interviewed and examined all patients
according to a standardized protocol, assessing current
age, age at diagnosis of Type 1 DM, duration of diabetes
(years), monthly family income in minimum wages, eco-
nomic class, physical activity (times per week) [17], height
(m), weight (kg), blood pressure (mmHg), insulin therapy
regimen, diabetes-related comorbidities, frequency of daily
self-monitoring of capillary blood glucose and smoking
status (defined as smoking more than one cigarette per
day at the time of the interview) [18].
The economic status was defined according to the
Brazilian Economic Classification Criteria, which also
considers education level, categorized as illiterate/
incomplete primary education, complete primary
education/incomplete secondary education, complete
secondary education/incomplete high school, complete
high school/some college, or complete college education.
For this analysis, the economic classes considered were
high, medium, low and very low [19].
Body mass index (BMI) (Kg/m2) was determined by
dividing the weight (kg) by height (m) squared. In adults
(people older than 19 years old) [20], overweight was de-
fined as a BMI ≥25 kg/m2 and obesity as a BMI ≥30 kg/m2
[21]. In children (people younger than 13 years old) and
adolescents (people between 13 and 19 years old) [20],
overweight was defined as a BMI ≥85th percentile for age
and gender, and obesity as a BMI ≥95th percentile for age
and gender [22].
The levels of HbA1c, fasting plasma glucose (FPG),
total cholesterol, LDL cholesterol, HDL cholesterol, and
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triglycerides measured during the last clinical visit were
obtained from the participants’ medical records. Within
one year of the study assessment, people with a diabetes
duration greater than or equal to five years from diagnosis
were screened for the following chronic diabetes-related
complications: retinopathy, clinical nephropathy, macrovas-
cular diseases (classified as clinical coronary artery disease,
stroke, and peripheral vascular disease) and foot pathologies.
HbA1c values were obtained using high-performance
liquid chromatography (HPLC) in 54.6 % and turbidim-
etry and in 40 % of cases; in the remaining patients we
used other methods. Levels of fasting and postprandial
glycemia, total cholesterol, HDL cholesterol and triglyc-
erides were measured by enzymatic techniques. LDL
cholesterol level was calculated using the Friedewald’s
equation. The American Diabetes Association’s (ADA)
goals for adequate metabolic and clinical control were
adopted by the Brazilian Type 1 Diabetes Study Group.
Health-related quality of life assessment
HRQoL was assessed by the EuroQol [23], a measure of
health status that includes two tools: the EQ-5D and the
EQ-VAS. The first one analyzes descriptively five dimen-
sions of problems (mobility, self-care, usual activities,
pain and discomfort, and anxiety and depression) on a
scale of three scores, graded from 1 to 3 (1 “I have no
problems”, 2 “I have some problems, ”3“ I have extreme
problems”). The EQ-VAS (overall health status) consists
of an analog scale from 0 (very bad state of health) to
100 (optimal health status), for the patient to check or
tell a value that reflects their perception of state of
health. The EuroQol is not reliable in individuals youn-
ger than 10 years old. Therefore, these participants were
excluded from the initial sample.
Data collected using EQ-5D can be presented in various
ways: presenting results from the descriptive system as a
health profile, presenting results of the EQ- VAS as a meas-
ure of overall self-rated health status, and presenting results
from the EQ-5D index value. In order to obtain the EQ-5D
index value, it is required a general population-based value
set (as opposed to a patient-based set). The rationale behind
this is that the values are supposed to reflect the prefer-
ences of local taxpayers and potential receivers of health-
care. However, in Brazil, there is not a population-based
index available yet. Information in the single index format
is useful, for example, in cost utility analysis, which is not
the purpose of the present study.
Statistical analysis
The study sample represented the distribution of Type 1
DM cases across four geographical regions in Brazil, esti-
mated using the overall population distribution reported
in the Brazilian Institute of Geography and Statistics’
(IBGE) population census of 2000 [24]. These data were
combined with the national estimates of diabetes preva-
lence, which were derived from a 1988 survey, to deter-
mine the minimum number of patients to be studied in
each region [25]. Three thousand four hundred fifty seven
patients would be necessary to identify a proportion of pa-
tients with adequate glycemic control of 10 %, with a 95 %
confidence and a margin of error of 1 %. This number was
rounded to 3,500 patients and distributed among the four
geographical regions [North: 266 (7.6 %); Northeast: 984
(28.1 %); Southeast: 1492 (42.6 %); South: 518 (14.8 %);
and Midwest: 240 (6.9 %) individuals]. A total of 3,591
patients were included in this study. Participants youn-
ger than 10 years old were excluded from the initial
sample of 3,591 individuals, so that the final sample
comprised 3,005 patients.
Categorical variables were presented as frequency (per-
centage). All normally distributed values were given as
mean ± standard deviation (SD) and all other values
were given as median (range). We used Chi-squared and
Fisher tests to compare categorical data, and Student-T
and Man-Whitney tests for comparisons between two
groups with numeric variables. To test the differences
among more than two groups, analysis of variance
(ANOVA) was performed for all normally distributed
variables, and Kruskal-Wallis test was used for the non-
normally distributed variables. For multiple comparisons,
the Tukey test (post-hoc) was used. For correlation analysis,
Pearson or Spearman tests were used.
A model of simple linear regression was used with the
EQ-VAS score as dependent variable and HbA1c as in-
dependent variable. In addition, we performed a model
of multiple regression analysis (stepwise forward), with
EQ-VAS score as dependent variable and HbA1c, prac-
tice of physical activity, duration of diabetes, age, and
micro and macrovascular complications as independent
variables. We have not included in the model the vari-
ables that did not present strong correlation with EQ-
VAS (monthly family income and economic status), and
FPG, which is inferior in reflecting glycemic control in
type 1 diabetic patients when compared to HbA1c. For
statistical purposes (both comparison and regression
models), we used the HbA1c levels measured by HPLC.
A two-sided p < 0.05 was considered statistically sig-
nificant. All data was stored and processed by EPIINFO
2000 and analyzed using the Statistical Package for the
Social Sciences version 20.0 (IBM, Chicago, IL, USA) and
Sigma Stat version 3.5 (Jandel Scientific Corporation,
Chicago, IL, USA).
Ethics, consent and permissions
Each center’s local ethics committee approved the study
(Appendix 1). Written informed consent was obtained
from all of the patients, or their legal parents or guard-
ians for children.
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Results
The general demographic and clinical data of the assessed
population are shown in Table 1.
Clinical and laboratorial data and the percentage of
participants who met the ADA’s criteria for appropriate
metabolic and clinical control are shown in Table 2.
Overweight was observed in 586 (19.5 %) participants.
Screening for chronic complications had not been per-
formed on the year prior to the study in 735 people
(24.4 %). Glycemic control was considered poor in 2,571
(85 %) individuals. The description of the EuroQol
results in the population of people with Type 1 DM in
Brazil also is presented in Table 2.
The assessment of health status by the EQ-VAS shows
that the average score assigned to general health in
Brazil is markedly lower than those found in two other
Type 1 DM population-based studies conducted in the
Northern hemisphere, as demonstrated in Table 3. Our
results indicated an average HbA1c of 9.4 % (79 mmol/
mol), higher than the mean values found in the Netherlands
Table 1 General demographic and clinical data of people with Type 1 DM in Brazil
Variables
Participants, n 3,005
Age, years ± SD 23.9 ± 10.8
Women, n (%) 1,700 (56)






≥ 30 126 (4.1)
Mean age at diagnosis of Type 1 DM, years ± SD 13 ± 7.9














Monthly family income, number of minimum wages ± SD 2.3 ± 1.4
Practice of physical activity, times per week ± SD 3.6 ± 1.4
Microvascular complications, n (%) 673 (29.6)
Macrovascular complications, n (%) 124 (5.5)




Intermediate- or long- and short-acting insulin 80.8
Amount of insulin usage, UI/Kg/day ± SD 0.9 ± 0.4
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(8.3 % or 67 mmol/mol) [26] and in the United Kingdom
(8.2 % or 66 mmol/mol) [27].
The Table 4 show the correlation between EQ-5D and
the variables that could possibly affect HRQoL.
Furthermore, we evaluated the clinical and laboratorial
variables that could influence the HRQoL of people with
Type 1 DM and the existence of possible correlations.
Individually, age, duration of diabetes, fasting blood glu-
cose and the presence of chronic complications presented
very poor correlations with EQ-VAS. The most significant
correlation was between EQ-VAS and HbA1c (Table 5).
Evaluating the simple linear regression model, using the
EQ-VAS score as a dependent variable and HbA1c as
independent variable, we found r2 = 0.04, p <0.001,
with an unstandardized coefficient (Beta 1) equal to −1.5
(95 % CI = −1.772 to −1.197). It implies that a 1 % reduc-
tion of HbA1c may lead to a 1.5 point elevation of overall
health status.
Finally, in the multiple regression model (stepwise for-
ward), with EQ-VAS score as dependent variable and
HbA1c, practice of physical activity, duration of diabetes,
age and micro and macrovascular complications as inde-
pendent variables, all of them were included on the
model, with p <0.05. Even though HbA1c was the most
important of the model, all variables combined were
capable of determining only 7.1 % of the overall health
status of people with Type 1 DM.
On a post-hoc analysis, we found that the North-
Northeast region presents a higher index in the assess-
ment of the overall health status compared to the
Southeast (North-Northeast = 74.6 ± 30 and Southeast =
70.4 ± 19, p <0.05). Additionally, the EQ-5D showed a
markedly lower frequency of self-reported anxiety-
depression in the North-Northeast compared to the other
regions of the country (North-Northeast = 1.53 ± 0.6,
Southeast = 1.65 ± 0.7, South = 1.72 ± 0.7 and Midwest =
1.67 ± 0.7, p <0.05).
Discussion
This is a population-based study evaluating the HRQoL
of people with Type 1 DM in the Southern hemisphere,
in a country of continental proportions such as Brazil.
The assessment of HRQoL by the EuroQol showed that
the average score assigned to general health in Brazil is
markedly lower than those found in two other Type 1
DM population-based studies conducted in Europe.
Additionally, our data suggest that a better glycemic
control could positively impact the health status of
people with Type 1 DM.
Since no Brazilian national data on the HRQoL of
people with Type 1 DM were available, we compared the
overall health status found in this study with those deter-
mined by similar European researches. Brazilian partici-
pants reported an inferior HRQoL when compared to
individuals with Type 1 DM in the Netherlands [26] and
in the United Kingdom [27]. The significant difference be-
tween the EQ-VAS scores found in the Northern and
Southern hemispheres may be related to the better socio-
economic status, health care system, level of education
Table 2 Clinical and laboratorial data and participants at ADA’s goal for adequate metabolic and clinical control and evaluation of
HRQoL of people with Type 1 DM in Brazil by EuroQol
Variables Mean ± SD Participants at goal N (%)
BMI, Kg/m2 22.6 ± 3.9 2,077 (70)
HbA1c, % (mmol/mol) 9.4 ± 2.4 (79 ± 3) 434 (15)
Fasting plasma glucose, mmol/l 10.2 ± 5.8 765 (28)
Total cholesterol, mmol/l 4.4 ± 1.1 1,854 (73)
Triglycerides, mmol/l 1.1 ± 0.8 1,919 (78)
LDL cholesterol, mmol/l 2.6 ± 2.1 1,403 (59)
HDL cholesterol, mmol/l 1.4 ± 0.4 1,809 (75)
EQ-VAS 72.5 ± 22 -
Pain and discomfort 1.37 ± 0.5 -
Anxiety and depression 1.63 ± 0.6 -
Usual activities 1.1 ± 0.3 -
Self-care 1.03 ± 0.2 -
Mobility 1.07 ± 0.3 -
Table 3 EQ- VAS scores in population-based studies on HRQoL
in Type 1 DM
Site Participants (N) EQ-VAS Authors (Year)
Netherlands 274 80.8 ± 15.2 Hart et al. (2003) [23]
United Kingdom 459 75.1 ± 18.4 Hopkins et al. (2012) [27]
Brazil 3,005 72.5 ± 22 Souza et al. (2015)
Braga de Souza et al. Health and Quality of Life Outcomes  (2015) 13:204 Page 5 of 9
and glycemic control of the European population. In the
present study, the majority of the 3,005 participants evalu-
ated presented poor glycemic control, overweight and
were not systematically screened for clinical complications
of diabetes. These findings can be considered alarming
and suggest that it is necessary and urgent to improve the
health care of people with Type 1 DM in Brazil.
The effect of glycemic control on HRQoL of people
with Type 1 DM remains controversial, with conflicting
studies pointing to opposite directions. The Diabetes
Control and Complications Trial (DCCT) [10] showed
that people with Type 1 DM undergoing intensive dia-
betes treatment do not face changes in the quality of
their lives, even while the rigor of their diabetes care
was increased. Additionally, HbA1c levels were not asso-
ciated with HRQoL or any other psychosocial factors in
a cohort of 52 adolescents with Type 1 DM. This study
suggested that even teenagers who are successfully
achieving HbA1c goals of therapy may perceive diabetes
as having a negative impact on their lives, be depressed,
and find diabetes difficult to manage [11]. In opposition,
Hoey et al. [28], evaluating over 2,000 adolescents with
Type 1 DM, found that better HbA1c levels were associ-
ated with lower impact, fewer worries, greater satisfac-
tion, and better health perception. Furthermore, the
Hvidoere Study Group has suggested that the outcomes
of diabetes care, assessed by HbA1c, are better in people
with a better QoL [12]. In addition, Hopkins et al. [27]
demonstrated that the U.K.-based Dose Adjustment for
Normal Eating (DAFNE), a structured education pro-
gram delivered in routine clinical practice, not only im-
proves HbA1c but also reduces psychological distress
(anxiety and depression) and improves perceived well-
being assessed by the EuroQol in Type 1 DM. Finally,
Cochran et al. [29], in a meta-analysis including 1,892
subjects with type 1 or 2 diabetes, documented that
people with diabetes experience improved QoL from
participation in diabetes self-management training pro-
grams, which is associated with better metabolic control.
Our results suggest that a better glycemic control could
be a tool for enhancing health status, but further prospect-
ive studies with intervention are necessary to confirm this
hypothesis.
In our study, variables such as age, economic class,
physical activities, micro and macrovascular complica-
tions, diabetes duration and fasting blood glucose indi-
vidually showed poor correlation with health status.
Hart et al. [30] also showed weak correlations between
HRQoL and micro and macrovascular complications. It
suggests the existence of additional variables not yet
evaluated that could be determinant of HRQoL in those
individuals. It has been reported that diabetes mellitus is
associated with lower levels of vitamin D [31], which
might increase the prevalence of numerous comorbidi-
ties, such as depression [32]. In our study, the higher
EQ-VAS score and lower frequency of self-reported
anxiety-depression in the North-Northeast region of
Brazil could be influenced by vitamin D deficiency.
Table 4 Correlation between EQ-5D and variables that could possibly affect HRQoL
Variables Pain and discomfort Anxiety and depression Usual activities Self-care Mobility
Age (years) r 0,23 0,06 0,22 0,12 0,21
p <0.05 <0.05 <0.05 <0.05 <0.05
Duration of diabetes (years) r 0,15 0,04 0,17 0,11 0,18
p <0.05 <0.05 <0.05 <0.05 <0.05
HbA1c % (mmol/mol) r 0.05 0,05 −0,02 −0,01 −0,03
p <0.05 <0.05 NS NS NS
Micro and macrovascular complications (%) r −0,18 −0,07 −0,18 −0,09 −0,20
p <0.05 <0.05 <0.05 <0.05 <0.05
Physical activity (times per week) r −0,10 −0,07 −0,09 −0,08 −0,09
p <0.05 <0.05 <0.05 <0.05 <0.05
NS not significant
Table 5 Correlation between EQ-VAS and the variables that
could possibly affect HRQoL
Variables EQ-VAS
r P
Age (years) −0.1 <0.05
Duration of diabetes (years) −0.1 <0.05
Practice of physical activity (times per week) 0.15 <0.05
Economic status % −0.05 <0.05
Monthly family income number of minimum wages 0.03 NS
Fasting plasma glucose mmol/l −0.1 <0.05
HbA1c % (mmol/mol) −0.2 <0.05
Microvascular complications (%) −0.1 <0.05
Macrovascular complications (%) −0.1 <0.05
Micro and macrovascular complications (%) −0.1 <0.05
NS not signifficant
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Decreased vitamin D levels tend to be more common in
regions of lower sunlight exposure, such as the South and
Southeast of Brazil. In a study of 102 non-institutionalized
and low-income elderly, in Porto Alegre (Brazilian South
region), the prevalence of vitamin D deficiency reached
85.7 % [33]. On the other hand, a study in children in Re-
cife (Brazilian Northeast region) virtually detected no cases
of vitamin D deficiency [34]. Other factor possibly related
to a poorer quality of health could be the stressful lifestyle
of largely populated cities. The lower frequency of anxiety-
depression found in Brazilian North-Northeast, a region
with smaller population density, reinforces that hypothesis.
The main strengths of this study are as follows: 1) the
development a population-based study on HRQoL of
people with Type 1 DM in the Southern hemisphere; 2)
the recruitment of a large and representative population-
based cohort with Type 1 DM, in a country of continental
proportions such as Brazil; 3) the construction of a national
database for tracking these individuals in the long term.
It is also pertinent to reflect on potential shortcom-
ings. The present study may be limited by the self-report
nature of doctor-diagnosed diabetes, as there could be
misclassification of diabetes, once C-peptide and auto-
antibodies were not measured. Moreover, all participants
of this study were from secondary and tertiary levels of
care, and lived in large cities. Although the information
about the HRQoL of people treated at primary level has
not been achieved, these individuals probably represent
a minority of people with Type 1 DM in Brazil. Add-
itionally, the lack of standardization for the assessment
of HbA1c could have influenced the results, but in most
cases both methods were used and a strong correlation
was observed between them. Furthermore, the lack of
standard measures and scales makes it difficult to com-
pare the results of different populations on HRQoL [35].
However, proving to be an extremely useful and reliable
tool, the EuroQol questionnaire has been used in most
global multicenter studies evaluating health status in pa-
tients with diabetes. In Brazil, there is not a validated
EQ-5D index yet, which would allow us to compare the
data more precisely. Thus, the present study is a pilot
that must be expanded. Additionally, we did not dispose
of the individual data from the European studies to com-
pare to ours. It would also be of great interest to per-
form a meta-analysis including worldwide trials on
HRQoL in people with Type 1 DM, so we could deter-
mine more precisely the variables involved in the overall
health status, and develop strategies to improve the
well-being and satisfaction of these individuals.
Conclusions
In conclusion, this is a population-based study evaluating
the HRQoL of people with Type 1 DM in the Southern
hemisphere and in a country like Brazil, of continental
proportions. Our data indicate a worse quality of health of
people with Type 1 DM in Brazil in comparison to
Europe, and suggest that a better glycemic control
could positively impact the HRQoL of these individuals.
However, our study points to the existence of additional
factors not yet evaluated that could be determinant in the
HRQoL of people with Type 1 DM. A meta-analysis in-
cluding worldwide trials would be very useful to identify
these possible factors.
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(luescher_@hotmail.com), Renata Szundy Berardo,
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Hospital of São Paulo, São Paulo: Marcia Nery*, M.D.
(marcianery@hcnet.usp.br), Catarina Cani, M.D.
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Maria de Noronha, M.D. (renata_noronha@uol.com.br);
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